Antibacterial and anti-inflammatory agents that target endotoxin.
Antibiotic-resistant bacterial infections are a major clinical problem. Lipid A, the active part of lipopolysaccharide endotoxins in Gram-negative bacteria, is an intriguing target for new antibacterial and anti-inflammatory agents. Inhibition of lipid A biosynthesis kills most Gram-negative bacteria, increases bacterial permeability to antibiotics and decreases endotoxin production.